OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hill on the Approval of Brexucabtagene Autoleucel in MCL

November 4th 2020

Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL

November 4th 2020

Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Srinivasan on the Challenges of Developing New Therapies in Rare RCC Subtypes

November 4th 2020

Ramaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.

Dr. Luke on the Role of Targeted Therapy in Melanoma

November 4th 2020

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Dr. Pemmaraju on a New Era of Treatment Strategies in BPDCN

November 4th 2020

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

Dr. Tap on Future Research Efforts in Sarcoma

November 4th 2020

William D. Tap, MD, discusses future research efforts in sarcoma.

Dr. Mascarenhas on Limitations With JAK Inhibitors in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Dr. Bekaii-Saab on the Future of Telemedicine in CRC

November 4th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

Dr. Beltran on the Need to Identify Non–AR Targets in Prostate Cancer

November 3rd 2020

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

Dr. Vorobiof on Financial Toxicity in Oncology

November 3rd 2020

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Dr. Lonial on the Role of BCMA in Multiple Myeloma

November 2nd 2020

Sagar Lonial, MD, FACP, discusses the role of BCMA as a target in multiple myeloma.

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

Dr. Mahal on the Prevalence of Prostate Cancer in African American Men

November 2nd 2020

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men.

Dr. Salani on Therapeutic Advances in Endometrial Cancer

November 2nd 2020

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma

November 2nd 2020

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML

November 2nd 2020

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

October 30th 2020

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Dr. Tap on the Rise of Precision Medicine in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.